Trofinetide (DrugBank: Trofinetide)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 156 | レット症候群 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04279314 (ClinicalTrials.gov) | January 29, 2020 | 19/2/2020 | Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome | A 40-Week, Open-label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome | Rett Syndrome | Drug: Trofinetide | ACADIA Pharmaceuticals Inc. | NULL | Enrolling by invitation | 5 Years | 21 Years | Female | 180 | Phase 3 | United States |
| 2 | NCT04181723 (ClinicalTrials.gov) | November 6, 2019 | 26/11/2019 | Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome | Rett Syndrome | Drug: Trofinetide;Other: Placebo | ACADIA Pharmaceuticals Inc. | NULL | Recruiting | 5 Years | 20 Years | Female | 184 | Phase 3 | United States |